Enzalutamide

CAS 915087-33-1 29 current records 1 historicalSmall Molecule

Who holds supplier records for Enzalutamide? 29 organisations hold a current record for Enzalutamide: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (17), China (6), Netherlands (2), Taiwan (1) and 1 other country (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Enzalutamide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/enzalutamide

Reading the evidence

  • 29 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    17 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Enzalutamide expires 23 Feb 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (29)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Enzalutamide. Country is the organisation's recorded country, not necessarily the manufacturing site.

India17China6Netherlands2Taiwan1Poland1Country not recorded for 2
Need Enzalutamide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Enzalutamide are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • MYLAN LABORATORIES LTD
    Inactive DMF 30010 · filed Nov 2015

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (5 listed products contain Enzalutamide). The latest listed patent expires 23 Feb 2037. The latest listed exclusivity ended 17 Nov 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Enzalutamide is an androgen receptor inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer. It works by blocking the action of male hormones that fuel the growth of cancer cells in the prostate.

Chemical identity

IUPAC name
4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
Canonical SMILES
CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChIKey
WXCXUHSOUPDCQV-UHFFFAOYSA-N
Synonyms
Xtandi API, mdv 3100, mdv-3100, mdv3100, xtandi

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Androgen Receptor Inhibitor
Mechanism of action
Androgen Receptor Antagonists; Cytochrome P450 2C19 Inducers; Cytochrome P450 2C9 Inducers; Cytochrome P450 3A4 Inducers

Therapeutic areas

Prostate CancerHormonal TherapyCancer

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Enzalutamide?

29 organisations hold an active US FDA Type II Drug Master File or a CEP for Enzalutamide: Dr. Reddy's Laboratories Ltd. (India), Zydus Lifesciences Limited (India), AARTI PHARMALABS LIMITED (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (India), Aurisco Pharmaceutical Co.,ltd (China) and BDR LIFESCIENCES PRIVATE LIMITED (India), and 21 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Enzalutamide Drug Master Files are active?

Dr. Reddy's Laboratories Ltd. (DMF 29117, 41429), Zydus Lifesciences Limited (DMF 30304, 34489), AARTI PHARMALABS LIMITED (DMF 35618), Alembic Pharmaceuticals Limited (DMF 43204), ALIVUS LIFE SCIENCES LTD (DMF 39103), AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (DMF 43581), Aurisco Pharmaceutical Co.,ltd (DMF 34886) and BDR LIFESCIENCES PRIVATE LIMITED (DMF 40067) and 21 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Enzalutamide records mean?

1 organisation has only inactive Type II DMFs for Enzalutamide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Enzalutamide?

Yes. The latest patent listed for an approved US product containing Enzalutamide expires 23 Feb 2037, across 5 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Enzalutamide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Enzalutamide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.